Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2010, for Zeta Acquisition Corp. II (not Whitehawk Therapeutics, Inc., as indicated in the metadata). The registrant is a Delaware corporation organized as a "blank check" company and a shell company. Its sole business objective is to investigate and acquire a target company to achieve long-term growth potential. The company has no specific business plan other than to merge with an unidentified company and has generated no revenues since its inception on November 16, 2007.
Key Financial Metrics
| Metric | Value (as of/for period ended Sep 30, 2010) |
|---|---|
| Revenue | $0 (No revenue generated since inception) |
| Net Loss (9 months) | $(14,649) |
| Net Loss (Cumulative) | $(83,245) |
| Cash and Cash Equivalents | $2,254 |
| Total Assets | $6,004 |
| Total Liabilities | $39,249 |
| Stockholders' Deficit | $(33,245) |
| Notes Payable (Stockholders) | $35,000 |
| Operating Cash Flow (9 months) | $(18,888) |
Material Changes vs. Prior Period
- Liquidity Decline: Cash and cash equivalents decreased from $11,142 at December 31, 2009, to $2,254 at September 30, 2010, a reduction of approximately 80%.
- Increased Debt: Notes payable to stockholders increased by $10,000 during the nine-month period, rising from $25,000 to $35,000.
- Accumulated Deficit: The accumulated deficit grew from $(68,596) to $(83,245) due to ongoing operating losses.
- Expense Comparison: Net loss for the nine months ended September 30, 2010, was $(14,649), compared to $(12,529) for the same period in 2009.
Outlook, Risks, and Management Commentary
Going Concern Uncertainty: Management explicitly states that the company's ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or obtain necessary financing. The company has no assurance it can satisfy cash requirements for the next twelve months.
Capital Resources: The company is dependent on related parties (stockholders and management) for continued funding. It currently holds only $2,254 in cash. Future funding is expected to come from equity financing via a reverse merger or additional related-party advances.
Risks:
- Shell Company Status: As a shell company with nominal assets, the company has no operations and relies entirely on a future business combination.
- Target Selection: The company may acquire financially unstable or early-stage companies, introducing significant operational and financial risks.
- Lack of Diversification: Management anticipates effecting only one business combination, meaning the company cannot offset losses from one venture against gains from another.
Unusual Items: The company utilizes office space and equipment of an officer/director at no cost, which management estimates to be de minimis.
Investor Verification Checklist
- Company Identity: Verify that the filing is for Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc.
- Cash Runway: Confirm the current cash balance of $2,254 is sufficient to meet immediate filing and administrative obligations.
- Related Party Debt: Review the terms of the $35,000 in notes payable to stockholders, which bear 6% interest and are due on demand.
- Going Concern Status: Assess the likelihood of securing additional financing or a business combination before cash is depleted.
- Share Count: Note that 5,000,000 shares of common stock are outstanding as of November 15, 2010.